Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARCT-2304 Pandemic Influenza Vaccine in Healthy Adults
NCT06602531Phase 2Completed
- Sponsor
- Arcturus Therapeutics
- Start
- Dec 2024
- Primary completion
- Jun 2025
- Modality
- Nanoparticles, Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ARCT-2304 in influenza (16 arms), sponsored by Arcturus Therapeutics. Primary endpoints: Number of Participants With Solicited Adverse Events, Number of Participants With Unsolicited Adverse Events and 9 more. Started Dec 2024; status: completed.
02
Drugs
ARCT-2304
03
Conditions
influenza
Beyond the preview
Go deeper on NCT06602531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06602531.